PARIS, December 13 /PRNewswire/ -- "We need to concentrate on the most cost-effective measures to reduce CO2 emissions in transport", stressed Jack Short, Secretary General of the International Transport Forum, at the United Nations Climate Change Conference in Bali on Thursday. Too often high cost and low impact measures are being chosen, he criticised. Because the challenge for the sector to reduce its CO2 emissions is immense, neither industrial nor developing countries can afford to get priorities wrong. "By achieving the required emission reductions at the lowest overall cost, it is possible to protect the climate with minimal damage to welfare and economic growth."

GENEVA, Switzerland, December 13 /PRNewswire/ --

- Merck Serono Will Fund a US$2 Million Initiative to Drive Treatments for Parkinson's Disease-Related Cognitive Dysfunction and Mood Disorders

Merck Serono, a division of Merck KGaA of Darmstadt, Germany, is supporting the US$2-million commitment of The Michael J. Fox Foundation for Parkinson's Research (MJFF) for research toward therapies to alleviate Parkinson's disease (PD)-related cognitive dysfunction and mood disorders. The funding is to be awarded under a new initiative, Cognitive Deficits and Mood Disorders in Parkinson's Disease.

LEEDS, England, December 13 /PRNewswire/ -- Teva UK Limited has announced plans to expand and strengthen its supply chain warehouse and logistic centre, and at the same time relocate its UK head office to new premises.

The company is planning to move its head office to Glasshoughton in West Yorkshire, at the junction of the M62 and A1 trunk roads, by the end of next year. The move will put the company's main logistics centre, as well as over 150 head office staff, in a brand-new expanded site that has a capacity no less than five times bigger than the firm's existing site near Leeds.

MALVERN, Pennsylvania, December 13 /PRNewswire/ --

- Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for In-Person Workshops

In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created MYOBLOC(TM) University, an online, self-study resource that incorporates new learning technology. The course integrates multi-dimensional, life-like animation throughout the content -- with anatomy based on real patients with CD and actual injection technique demonstrations with Myobloc(R) (Botulinum Toxin Type B) Injectable Solution. The course can be accessed at www.myoblocuniversity.com.

LONDON, December 13 /PRNewswire/ --

Qualcomm Incorporated (Nasdaq: QCOM), a leading developer and innovator of advanced wireless technologies and data solutions, today announced that it has signed an agreement with Ecole Polytechnique Federale de Lausanne (EPFL), a leading European technical university. According to the agreement, Qualcomm now owns certain intellectual property rights directed to signal processing and will provide a research grant to EPFL. The research grant will enable EPFL to continue its pioneering research and work with Qualcomm to generate research ideas that can ultimately lead to commercial products.

SAN FRANCISCO, December 13 /PRNewswire/ -- Synosia Therapeutics today announced the appointment of Antony Blanc, Ph.D., as the company's new chief business officer, effective immediately.

Dr Blanc, who will serve as head of Synosia's office in Basel, Switzerland, joins from Syngenta, where he created and led the biopharmaceuticals business unit. A molecular biologist by training and an experienced biotech entrepreneur, Dr. Blanc helped biotech and pharma clients with R&D, commercial and strategy issues as associate partner with the business consultants McKinsey & Company.